Zepbound tirzepatide

Drug Class

Dual GIP and GLP-1 receptor agonist

Mechanism

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that acts on receptors to decrease calorie intake and reduce body weight by delaying gastric emptying and increasing satiety.

Approved Indication

Chronic weight management in adults with obesity (BMI >=30 kg/m2) or overweight (BMI >=27 kg/m2) with at least one weight-related comorbidity.

What This Means For Patients

Zepbound is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• SURMOUNT-1 — Jastreboff et al., N Engl J Med 2022 (NCT04184622) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217820s000lbl.pdf
• https://www.lilly.com/news/media-releases/fda-approves-lillys-zepbound-tirzepatide-for-chronic-weight-management
• http://www.nmpa.gov.cn/